DOI: https://doi.org/10.24959/nphj.18.2198

The marketing research of the Ukrainian market of drugs for the treatment of arthritis

М. M. Postoy, L. I. Vyshnevska

Abstract


Rheumatoid arthritis (RA) is a chronic systematic disease of the connective tissue with peripheral joints damage and characteristic non-arterial effects. Rheumatic diseases affect the national economy, lead to considerable expenses for their treatment and reduce the quality of the patients’ life.

Aim. To study drugs used for the treatment of arthritis at the Ukrainian pharmaceutical market, determine the number of the domestic and imported producers.

Materials and methods. The analysis of the drug assortment was conducted in accordance with the State Register of Drugs of Ukraine and ATC-classification of the WHO. The sources of information used were Compendium 2016 – Drugs, and a Software Complex, a weekly journal “Pharmacy online”.

Results and discussion. It has been determined that the leading position of producers of drugs for the treatment of RA belongs to national manufacturers, and there is also a significant market share in manufacturers from Germany, Switzerland and Israel. By the pharmacological action the most common group (26 %) is presented by anti-inflammatory and anti-rheumatic drugs; 25 % of foreign and domestic drugs are antiviral drugs; 19 % are other drugs used in pathology of the locomotor system. The majority group of medicines consists of tablets, capsules and injectable dosage forms.

Conclusions. According to the ATC-classification data there are approximately 60 drugs presented at the pharmaceutical market of Ukraine for the treatment of rheumatic diseases. This market segment includes different pharmacotherapeutic groups, a wide range of manufacturing countries and pharmaceutical companies. However, there is no original combined gel of the complex national production at the pharmaceutical market of Ukraine. 


Keywords


rheumatoid arthritis; marketing analysis; pharmaceutical market; gel

Full Text:

PDF

References


Kovalenko, N. A., Supichenko, G. N., Leontev, V. N., Shutova, A. G., Kulinchik, A. I. (2010). Zhurnal Trudy BGTU, 1 (4).

Agarwal, S. K. (2011). Core Management Principles in Rheumatoid Arthritis to Help Guide Managed Care Professionals. Journal of Managed Care Pharmacy, 17 (9 Supp B), S03–S08. doi: 10.18553/jmcp.2011.17.s9–b.s03

Morozov, A. M., Yakovlieva, L. V., Bezditko, N. V. et al. (2013). Otsinka klinichnoi ta ekonomichnoi dotsilnosti vykorystannia likarskykh zasobiv u likuvalno–profilaktychnomu zakladi (suprovid formuliarnoi systemy). Kharkiv: Styl–Yzdat, 36.

Klimeš, J., Vocelka, M., Šedová, L., Doležal, T., Mlčoch, T., Petříková, A., Vlček, J. (2014). Medical and Productivity Costs of Rheumatoid Arthritis in The Czech Republic: Cost–of–Illness Study Based on Disease Severity. Value in Health Regional Issues, 4, 75–81. doi: 10.1016/j.vhri.2014.07.004

Gaujoux–Viala, C., Smolen, J. S., Landewe, R., Dougados, M., Kvien, T. K., Mola, E. M., Gossec, L. (2010). Current evidence for the management of rheumatoid arthritis with synthetic disease–modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 69 (6), 1004–1009. doi: 10.1136/ard.2009.127225

Nam, J. L., Winthrop, K. L., van Vollenhoven, R. F., Pavelka, K., Valesini, G., Hensor, E. M. A., Buch, M. H. (2010). Current evidence for the management of rheumatoid arthritis with biological disease–modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Annals of the Rheumatic Diseases, 69 (6), 976–986. doi: 10.1136/ard.2009.126573

Meier, F. M., Frerix, M., Hermann, W., Müller–Ladner, U. (2013). Current immunotherapy in rheumatoid arthritis. Immunotherapy, 5 (9), 955–974. doi: 10.2217/imt.13.94

8. Derzhavnyi reiestr likarskykh zasobiv Ukrainy. (2015). Kyiv: MOZ Ukrainy. Available at: http: // www. drlz.kiev.ua

Blikhar, V. Ye., Maltsev, V. I., Morozov, A. M., Parii, V. D., Stepanenko, A. V., Dumenko, T. M. (2012). Derzhavnyi formuliar likarskykh zasobiv. Kyiv, 4, 1159.

Kovalenko, V. N. (2015). Kompendium 2016 – lekarstvennye preparaty. Kiev: Morion, 1408.


GOST Style Citations


1.         Химия, технология органических веществ и биотехнология / Н. А. Коваленко, Г. Н. Супиченко, В. Н. Леонтьев и др. // Журн. «Труды БГТУ». – 2010. – Том 1, № 4.

2.         Agarwal, S. K. Core Management Principles in Rheumatoid Arthritis to Help Guide Managed Care Professionals / S. K. Agarwal // J. of Managed Care Pharmacy. – 2011. – Vol. 17, Issue 9, Supp B. – Р. S03–S08. doi: 10.18553/jmcp.2011.17.s9–b.s03

3.         Оцінка клінічної та економічної доцільності використання лікарських засобів у лікувально–профілактичному закладі (супровід формулярної системи) : метод. рек. / А. М. Морозов, Л. В. Яковлєва, Н. В. Бездітко та ін. – Х. : Стиль–Издат, 2013. – 36 с.

4.         Medical and Productivity Costs of Rheumatoid Arthritis in TheCzech Republic: Cost–of–Illness Study Based on Disease Severity / J. Klimes, M. Vocelka, L. Sedova et al. // Value in Health. Regional Issues. – 2014. – Vol. 4. – P. 75–81. doi: 10.1016/j.vhri.2014.07.004

5.         Current evidence for the management of rheumatoid arthritis with synthetic disease modifying anti–rheumatic drugs : a systematic literature review in forming the EULAR recommendations for the management of rheumatoid arthritis / C. Gaujoux–Viala, J. Smolen, R. Landewe et al. // Ann. Rheum. Dis. – 2010. – Vol. 69, Issue 6. – Р. 1004–1009. doi: 10.1136/ard.2009.127225

6.         Current evidence for the management of rheumatoid arthritis with biological disease modifying anti–rheumatic drugs : a systematic literature review informing the EULAR recommendations for the management of RA / J. Nam, K. Winthrop et al. // Ann. Rheum. Dis. – 2010. – Vol. 69, Issue 6. – Р. 976–986. doi: 10.1136/ard.2009.126573

7.         Current immunotherapy in rheumatoid artritis / F. M. Meier, M. Frerix, W. Hermann, U. Muller–Ladner // Immunotherapy. – 2013. – Vol. 5, Issue 9. – P. 955–974. doi: 10.2217/imt.13.94

8.        Державний реєстр лікарських засобів України [Електронний ресурс]. – К. : МОЗ України, 2015. – Режим доступу : http: // www. drlz.kiev.ua

9.         Державний формуляр лікарських засобів / ред. кол. В. Є. Бліхар, В. І. Мальцев, А. М. Морозов та ін. – К., 2012. – Вип. 4. – 1159 с.

10.       Компендиум 2016 – лекарственные препараты / под ред. В. Н. Коваленко. – К. : Морион, 2015. – 1408 с.





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Vìsn. farm.

ISSN 2415-8844 (Online), ISSN 1562-7241 (Print)